Log In
Print
BCIQ
Print
Print this Print this
 

Rozerem, ramelteon (TAK-375)

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionMelatonin MT1 and MT2 receptors agonist
Molecular Target Melatonin MT1 receptor ; Melatonin MT2 receptor
Mechanism of ActionMelatonin MT2 receptor agonist; Melatonin MT1 receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInsomnia
Indication DetailsTreat chronic insomnia; Treat chronic transient insomnia; Treat circadian rhythm sleep disorder; Treat insomnia; Treat primary insomnia; Treat transient insomnia
Regulatory Designation

Partner

Meiji Seika Pharma Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today